A multicenter evaluation of a deep learning software (LungQuant) for lung parenchyma characterization in COVID-19 pneumonia

Abstract

Background The role of computed tomography (CT) in the diagnosis and characterization of coronavirus disease 2019 (COVID-19) pneumonia has been widely recognized. We evaluated the performance of a software for quantitative analysis of chest CT, the LungQuant system, by comparing its results with independent visual evaluations by a group of 14 clinical experts. The aim of this work is to evaluate the ability of the automated tool to extract quantitative information from lung CT, relevant for the design of a diagnosis support model. Methods LungQuant segments both the lungs and lesions associated with COVID-19 pneumonia (ground-glass opacities and consolidations) and computes derived quantities corresponding to qualitative characteristics used to clinically assess COVID-19 lesions. The comparison was carried out on 120 publicly available CT scans of patients affected by COVID-19 pneumonia. Scans were scored for four qualitative metrics: percentage of lung involvement, type of lesion, and two disease distribution scores. We evaluated the agreement between the LungQuant output and the visual assessments through receiver operating characteristics area under the curve (AUC) analysis and by fitting a nonlinear regression model. Results Despite the rather large heterogeneity in the qualitative labels assigned by the clinical experts for each metric, we found good agreement on the metrics compared to the LungQuant output. The AUC values obtained for the four qualitative metrics were 0.98, 0.85, 0.90, and 0.81. Conclusions Visual clinical evaluation could be complemented and supported by computer-aided quantification, whose values match the average evaluation of several independent clinical experts. Key points We conducted a multicenter evaluation of the deep learning-based LungQuant automated software. We translated qualitative assessments into quantifiable metrics to characterize coronavirus disease 2019 (COVID-19) pneumonia lesions. Comparing the software output to the clinical evaluations, results were satisfactory despite heterogeneity of the clinical evaluations. An automatic quantification tool may contribute to improve the clinical workflow of COVID-19 pneumonia.

Radiomics Applications in Spleen Imaging: A Systematic Review and Methodological Quality Assessment

“…Finally, another clinical scenario where radiomic features extracted from the spleen were helpful in clinical decision making is COVID-19. The value of lung parenchymal quantitative imaging biomarkers for COVID-19 diagnosis and severity assessment has been already widely proven in the literature [ 39 , 40 , 41 ]. However, COVID-19 is known to also involve other organs [ 42 ].…”

Fighting against COVID‐19: Innovations and applications

“…Chest x‐ray radiograph (CXR) has been an important tool in the fight against COVID‐19, 12 particularly in the early stages of the pandemic when testing for the virus was limited. X‐rays can detect signs of COVID‐19 in the lungs, aiding in diagnosing and managing the disease 13 .…”

Accuracy of artificial intelligence CT quantification in predicting COVID-19 subjects’ prognosis

“…A deep learning tool named LungQuant was employed to characterize lung parenchyma in COVID-19 pneumonia. The AUC values for percentage of lung involvement and type of lesion were reported as 0.98 and 0.85, respectively [28]. In another investigation, AI was harnessed to identify pulmonary vascular-related structures (VRS).…”